← Back to Search

Whole Blood Transfusion for Trauma Patients

Phase 3
Waitlist Available
Research Sponsored by Loma Linda University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult male patients brought into the emergency department as LEVEL A trauma activations who are receiving emergency blood transfusions
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours post ed admission
Awards & highlights

Study Summary

This trial is looking at whether or not adult male patients who are brought to the emergency department as Level A trauma activations and are receiving emergency blood transfusion benefit from receiving more blood.

Eligible Conditions
  • Acute Blood Loss Anemia
  • Hemorrhagic Shock
  • Traumatic Brain Injury

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Adult men brought to the emergency room as severe trauma cases and receiving emergency blood transfusions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours post ed admission
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours post ed admission for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
pRBC equivalents transfused
Secondary outcome measures
Mortality

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Low Titer O+ Whole BloodExperimental Treatment1 Intervention
Low Titer O+ Whole blood provided to Level A trauma patients
Group II: Component TherapyActive Control1 Intervention
Component Therapy of O+ pRBC and FFP dispatched to trauma bay for level A traumas
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Routine labs
2022
Completed Phase 3
~210

Find a Location

Who is running the clinical trial?

Loma Linda UniversityLead Sponsor
304 Previous Clinical Trials
259,287 Total Patients Enrolled
1 Trials studying Anemia
299 Patients Enrolled for Anemia

Media Library

Component Therapy Clinical Trial Eligibility Overview. Trial Name: NCT05081063 — Phase 3
Anemia Research Study Groups: Low Titer O+ Whole Blood, Component Therapy
Anemia Clinical Trial 2023: Component Therapy Highlights & Side Effects. Trial Name: NCT05081063 — Phase 3
Component Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05081063 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any enrolment opportunities for this experiment?

"Confirmed. The information on clinicaltrials.gov depicts that this study, which was initially published on March 5th 2022, is currently seeking out suitable participants. Approximately 200 volunteers need to be recruited from 1 medical centre."

Answered by AI

How many volunteers have enrolled in this research project?

"Affirmative. Information hosted on clinicaltrials.gov verifies that this medical trial, which was initially posted on March 5th 2022, is currently recruiting participants. Approximately 200 subjects need to be enrolled from 1 health facility."

Answered by AI
Recent research and studies
~65 spots leftby Apr 2025